U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service - STAT
	Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs - Pharmaceutical Technology
	NICE rejects Lilly‘s Kisunla and Eisai‘s Leqembi - BioWorld MedTech
	Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.” - Eisai
	Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com
	Japanese drugmaker Eisai lays off 57 from U.S. headquarters - NJ.com
	Eisai Wins Patent Dispute Blocking Shilpa Medicare’s Generic Lenvatinib Mesylate Until 2036 - geneonline.com
	Eisai Shares Rise as New Alzheimer’s Test Seen Helping Sales - Bloomberg.com